ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
ABBOTT LABORATORIES
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$104.06−0.83 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $181.37B
- P/E (TTM)
- 33.5
- Dividend yield
- 2.31%
ABBOTT LABORATORIES revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $21.39B | $18.99B | $16.89B | $14.80B | $14.49B | $11.79B | $12.24B | $11.37B | $10.33B | – | 48.2% | +12.6% |
| Diagnostic Products | $8.94B | $9.34B | $9.99B | $16.47B | $15.53B | $10.81B | $7.71B | $7.50B | $5.62B | $4.81B | 20.2% | -4.3% |
| Nutritional Products | $8.45B | $8.41B | $8.15B | $7.46B | $8.29B | $7.65B | $7.41B | $7.23B | $6.93B | $6.90B | 19.1% | +0.5% |
| Established Pharmaceuticals | $5.54B | $5.19B | $5.07B | $4.91B | $4.72B | $4.30B | $4.49B | $4.42B | $4.29B | $3.86B | 12.5% | +6.6% |
| Vascular Products | – | – | – | – | – | – | – | – | – | $2.90B | – | – |
| Cardiovascular and Neuromodulation Products | – | – | – | – | – | – | – | – | $8.91B | $2.90B | – | – |
| Cardiovascular and Neuromodulation Products | – | – | – | – | – | – | – | $9.44B | $8.91B | $2.90B | – | – |
| Other Segment | – | – | – | – | $52.00M | $66.00M | $57.00M | $62.00M | $237.00M | $2.39B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $7.21B | $6.15B | $5.31B | $4.44B | $4.53B | $3.04B | $3.77B | $3.50B | $3.01B | – | +17.2% |
| Diagnostic Products | $1.74B | $2.07B | $2.43B | $6.64B | $6.24B | $3.73B | $1.91B | $1.87B | $1.47B | $1.19B | -16.1% |
| Nutritional Products | $1.56B | $1.51B | $1.33B | $706.00M | $1.76B | $1.75B | $1.71B | $1.65B | $1.59B | $1.66B | +3.5% |
| Established Pharmaceuticals | $1.29B | $1.23B | $1.21B | $1.05B | $889.00M | $794.00M | $904.00M | $894.00M | $848.00M | $723.00M | +4.6% |
| Vascular Products | – | – | – | – | – | – | – | – | – | $1.04B | – |
| Cardiovascular and Neuromodulation Products | – | – | – | – | – | – | – | – | $2.72B | $1.04B | – |
| Cardiovascular and Neuromodulation Products | – | – | – | – | – | – | – | $2.99B | $2.72B | $1.04B | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $27.20B | $25.63B | $24.66B | $25.51B | $26.43B | $21.59B | $20.51B | $19.74B | $17.72B | – | 61.4% | +6.1% |
| United States | $17.13B | $16.32B | $15.45B | $18.14B | $16.64B | $13.02B | $11.40B | $10.84B | $9.67B | $6.49B | 38.6% | +4.9% |
| All Other Countries | $15.98B | $14.79B | $14.17B | $15.01B | $15.73B | $12.82B | – | – | – | – | 36.0% | +8.1% |
| Germany | $2.76B | $2.54B | $2.35B | $2.34B | $2.57B | $2.11B | $1.75B | $1.62B | $1.37B | $1.04B | 6.2% | +8.7% |
| China | $1.91B | $2.11B | $2.25B | $2.13B | $2.39B | $1.97B | $2.35B | $2.31B | $2.15B | $1.73B | 4.3% | -9.7% |
| India | $1.87B | $1.82B | $1.75B | $1.65B | $1.56B | $1.32B | $1.40B | $1.33B | $1.24B | $1.11B | 4.2% | +3.0% |
| Switzerland | $1.87B | $1.75B | $1.64B | $1.34B | $1.31B | $1.14B | $1.07B | $1.01B | $841.00M | $766.00M | 4.2% | +7.1% |
| Japan | $1.48B | $1.44B | $1.51B | $1.93B | $1.70B | $1.39B | $1.44B | $1.33B | $1.26B | $924.00M | 3.3% | +2.4% |
| United Kingdom | $1.34B | $1.19B | $991.00M | – | – | – | – | – | $498.00M | $377.00M | 3.0% | +13.1% |
| Canada | – | – | – | $1.28B | $1.39B | $841.00M | $573.00M | – | $443.00M | $408.00M | – | – |
| Italy | – | – | – | – | – | – | – | – | $507.00M | $365.00M | – | – |
| Netherlands | – | $1.12B | $1.07B | $1.11B | $1.17B | $1.08B | $975.00M | $930.00M | $929.00M | $830.00M | – | – |
| Brazil | – | – | – | – | – | – | – | – | $541.00M | $410.00M | – | – |
| Russia | – | – | – | – | – | – | – | – | $664.00M | $554.00M | – | – |
| Colombia | – | – | – | – | – | – | – | – | $494.00M | $424.00M | – | – |
| Vietnam | – | – | – | – | – | – | – | – | $427.00M | $434.00M | – | – |
| France | – | – | – | – | – | – | – | – | $628.00M | $352.00M | – | – |
| All Other Countries | – | – | – | – | $15.52B | $12.82B | $11.94B | $11.22B | $9.94B | $7.96B | – | – |
From the segment and revenue-disaggregation notes of Abbott Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.